Corcept Therapeutics
CORT
241 hedge funds and large institutions have $1.65B invested in Corcept Therapeutics in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 97 increasing their positions, 70 reducing their positions, and 30 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 70
23% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 30
1% more funds holding
Funds holding: 238 → 241 (+3)
5.73% less ownership
Funds ownership: 81.23% → 75.49% (-5.7%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
26% less capital invested
Capital invested by funds: $2.23B → $1.65B (-$581M)
73% less call options, than puts
Call options by funds: $3.53M | Put options by funds: $13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$13.8M |
| 2 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$12.2M |
| 3 |
BlackRock
New York
|
+$4.02M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$3.73M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$57.1M |
| 2 |
EIP
Epoch Investment Partners
New York
|
-$28.6M |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$25.4M |
| 4 |
D.E. Shaw & Co
New York
|
-$10.5M |
| 5 |
Janus Henderson Group
London,
|
-$7.13M |
CORT Hedge Fund Activity: Q4 2022 in Review
241 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2022, worth a combined $1.65B — down 26% from $2.23B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CORT positions and 30 closed out — a net gain of 7 holders — while 97 added to existing stakes and 70 trimmed.
The largest buyer was Woodline Partners, adding an estimated $13.8M. The largest seller was Federated Hermes, cutting an estimated $57.1M.
- 241 institutional investors held Corcept Therapeutics (CORT) as of Q4 2022, up from 238 in Q3 2022.
- Funds reported $1.65B of Corcept Therapeutics stock for Q4 2022, down 26% quarter-over-quarter.
- 37 funds opened new Corcept Therapeutics positions in Q4 2022 and 30 closed out, a net change of +7 holders.
- The largest Corcept Therapeutics buyer in Q4 2022 was Woodline Partners, an estimated $13.8M added.
- The largest Corcept Therapeutics seller in Q4 2022 was Federated Hermes, an estimated $57.1M sold.
Based on aggregated 13F filings for Q4 2022.